Showing 1,341 - 1,360 results of 21,342 for search '(( significant risks decrease ) OR ( ((significant decrease) OR (significant increase)) decrease ))', query time: 0.59s Refine Results
  1. 1341
  2. 1342
  3. 1343
  4. 1344
  5. 1345
  6. 1346

    The strength of the commute time-functional connectivity relationship demonstrates weak pathological significance and weak dependency on age. by Rostam M. Razban (22232522)

    Published 2025
    “…</b> Strengthening commute time-FC correlations shown in <b>B</b> seem to be driven by a decrease in average commute time across age. Note that all reported correlations are calculated by considering all data points, i.e., they are not calculated for the binned data.…”
  7. 1347
  8. 1348
  9. 1349

    Livestock–Crop–Mushroom (LCM) Circular System: An Eco-Friendly Approach for Enhancing Plant Performance and Mitigating Microbiological Risks by Dong Liu (115204)

    Published 2025
    “…The two biofertilizers were tested for their impacts on plant growth and potential microbial risks. The results show significant growth of oats stimulated by biofertiliser use. …”
  10. 1350

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  11. 1351

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  12. 1352

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  13. 1353

    Table_1_FMT intervention decreases urine 5-HIAA levels: a randomized double-blind controlled study.DOCX by Lihong Wang (14991)

    Published 2024
    “…However, in the placebo group, GSRS, CARS, and SRS scores showed no significant changes, while ABC scores decreased from 72 to 58.75 (p = 0.034). …”
  14. 1354
  15. 1355
  16. 1356
  17. 1357
  18. 1358
  19. 1359
  20. 1360